EpiBiologics is rethinking how medicines work by removing disease-causing proteins instead of merely blocking them. The San Mateo-based biotech has raised $107 million from investors including GV and Johnson & Johnson to advance its EpiTAC platform, with its first cancer therapy expected to enter human trials in early 2026. The approach could reshape future drug discovery.